. 2020 May 11;117(21):11685–11691. doi: 10.1073/pnas.1920346117

Table 5.

PVL, Southern blotting, next-generation sequencing, and mutation target sequencing results in HAM/TSP patients with more than 25% of CD4⁺ cells positive for CADM1 (n = 27)

HAM ID no.	PVL in PBMC	% in CD4⁺			Monoclonal band by Southern blot	% of major clone by NGS	Mutation by target sequence
HAM ID no.	PVL in PBMC	CADM1⁺	CADM1⁺CD7^dim	CADM1⁺CD7^neg	Monoclonal band by Southern blot	% of major clone by NGS	Mutation by target sequence
CD7^dim < CD7^neg
HAM1	3.89	63.90	5.04	58.86	+	41.26%	+
HAM2	2.31	27.13	12.81	14.32	—	2.25%	+
HAM3	12.93	67.28	33.97	33.31	+	10.70%	+
HAM4	14.79	43.82	9.29	34.53	+	NT	NT
HAM5	10.26	36.16	12.6	23.56	+	NT	NT
HAM6	12.78	35.40	13.32	22.08	+	10.52%	+
HAM7	21.57	42.92	20.04	22.88	+	9.92%	+
CD7^dim > CD7^neg
HAM8	25.50	33.99	26.71	7.28	—	1.16%	—
HAM9	9.52	39.49	31.68	7.81	—	2.75%	+
HAM10	6.11	30.69	23.00	7.69	—	3.44%	+
HAM11	10.83	30.22	22.36	7.86	—	4.02%	+
HAM12	8.10	26.98	18.51	8.47	—	2.36%	+
HAM13	6.78	33.17	21.72	11.45	—	NT	NT
HAM14	14.41	48.19	26.35	21.84	—	3.56%	+
HAM15	12.39	36.79	28.21	8.58	—	2.89%	+
HAM16	14.33	42.38	26.52	15.86	—	3.38%	+
HAM17	12.44	30.98	24.12	6.86	—	2.89%	+
HAM18	9.31	30.46	21.03	9.43	—	3.53%	+
HAM19	17.13	38.60	28.52	10.08	—	NT	NT
HAM20	10.49	30.87	20.42	10.45	—	4.34%	+
HAM21	17.54	52.60	37.77	14.83	—	NT	NT
HAM22	5.80	29.73	26.98	2.75	+	NT	NT
HAM23	20.26	37.80	28.65	9.15	—	4.04%	+
HAM24	13.27	26.75	19.09	7.66	—	2.39%	—
HAM25	9.99	34.53	25.19	9.34	+	43.06%	+
HAM26	12.70	33.32	21.07	12.25	—	14.56%	+
HAM27	22.17	55.65	44.48	11.17	+	72.96%	+

NGS, next-generation sequencing; NT, not tested; PVL, proviral load.